Overexpression of CD168 is related to poor prognosis in oral squamous cell carcinoma

Oral Dis. 2022 Mar;28(2):364-372. doi: 10.1111/odi.13766. Epub 2021 Jan 15.

Abstract

Objectives: Receptor for hyaluronic acid (HA)-mediated motility (RHAMM) is also known as CD168. This study proposed to elucidate the prognostic and clinicopathological significance of CD168 expression in oral squamous cell carcinoma (OSCC).

Materials and methods: Immune staining of a human tissue microarray and Western blot were used to reveal the expression level of CD168 in OSCC. Correlations between clinicopathological indexes and CD168 expression in OSCC patients were assessed.

Results: Increased expression of CD168 was detected in OSCC tissues. High expression of CD168 indicated worse survival of patients (p < .05). Furthermore, high expression of CD168 was related to pathological grade in OSCC (p < .05). CD168 expression was positively related to programmed death ligand 1 (PD-L1), CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6), B7 homology 4 protein (B7-H4), CD44, CD133, and Slug expression in OSCC.

Conclusion: This study revealed the overexpression of CD168 in OSCC and shed light on the prognostic significance of CD168 expression in OSCC patients.

Keywords: CD168; immunohistochemistry; oral squamous cell carcinoma; prognosis; tissue microarray.

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Carcinoma, Squamous Cell* / pathology
  • Head and Neck Neoplasms*
  • Humans
  • Mouth Neoplasms* / pathology
  • Prognosis
  • Squamous Cell Carcinoma of Head and Neck

Substances

  • Biomarkers, Tumor